{
    "clinical_study": {
        "@rank": "114563", 
        "brief_summary": {
            "textblock": "RATIONALE: Melphalan and colony-stimulating factors such as filgrastim may increase the\n      number of immune cells found in bone marrow or peripheral blood.\n\n      PURPOSE: Phase II trial to study the effectiveness of melphalan combined with filgrastim in\n      stimulating peripheral stem cells in patients who have multiple myeloma."
        }, 
        "brief_title": "Melphalan and Filgrastim to Stimulate Peripheral Stem Cells in Patients With Multiple Myeloma", 
        "completion_date": {
            "#text": "June 2003", 
            "@type": "Actual"
        }, 
        "condition": "Multiple Myeloma and Plasma Cell Neoplasm", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell", 
                "Plasmacytoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the safety and efficacy of melphalan when used with filgrastim (G-CSF) for\n           stem cell mobilization in patients with multiple myeloma.\n\n        -  Analyze how this mobilization regimen affects parameters of stem cell (CD34+)\n           mobilization and collection in these patients.\n\n        -  Determine how this mobilization regimen affects disease status and clonotypic (i.e.,\n           tumor cell) contamination in stem cell components in these patients.\n\n      OUTLINE: Patients undergo peripheral blood stem cell (PBSC) mobilization consisting of\n      melphalan IV on day 1 and filgrastim (G-CSF) subcutaneously beginning on day 2 and\n      continuing until PBSC collection is complete.\n\n      Patients are followed at 1 month.\n\n      PROJECTED ACCRUAL: A total of 11-32 patients will be accrued for this study within 2 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Diagnosis of multiple myeloma\n\n          -  Must have received induction therapy within the past 3 months\n\n          -  Chemoresponsive disease\n\n               -  Greater than 50% reduction of monoclonal paraprotein with reduction in marrow\n                  plasma cell infiltrate or greater than 50% reduction in marrow plasma cell\n                  infiltrate if disease is non-secretory\n\n          -  No symptomatic pleural effusions\n\n          -  Eligible for stem cell transplantation\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  ECOG 0-3 (ECOG 3 allowed only if due to bone disease or neuropathy)\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Platelet count at least 150,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin no greater than 2.5 mg/dL\n\n        Renal:\n\n          -  Creatinine no greater than 2.5 mg/dL OR\n\n          -  Creatinine clearance greater than 51 mL/min\n\n        Cardiovascular:\n\n          -  No symptomatic cardiomyopathy\n\n          -  No medically documented symptomatic cardiac arrhythmias within the past 60 days\n\n          -  No New York Heart Association class III congestive heart failure\n\n          -  No myocardial infarction within the past 6 months\n\n        Other:\n\n          -  No other concurrent medical conditions that would preclude study\n\n          -  No uncontrolled infections\n\n          -  No other active malignancy within the past 5 years except for non-melanoma skin\n             cancer\n\n          -  Not pregnant\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  No prior stem cell mobilization or transplantation\n\n        Chemotherapy:\n\n          -  See Disease Characteristics\n\n          -  No more than 200 mg prior oral melphalan\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  No more than 3000 cGy of prior radiotherapy for myeloma\n\n        Surgery:\n\n          -  Not specified"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "January 6, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00008268", 
            "org_study_id": "00-067", 
            "secondary_id": [
                "CDR0000068392", 
                "NCI-G00-1895"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "filgrastim", 
                "intervention_type": "Biological"
            }, 
            {
                "intervention_name": "melphalan", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Melphalan", 
                "Lenograstim"
            ]
        }, 
        "keyword": [
            "stage I multiple myeloma", 
            "stage II multiple myeloma", 
            "stage III multiple myeloma"
        ], 
        "lastchanged_date": "June 17, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/MSKCC-00067"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10021"
                }, 
                "name": "Memorial Sloan-Kettering Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II Study Of Blood Stem Cell Mobilization With Intravenous Melphalan (60 MG/M2) + G-CSF In Patients With Multiple Myeloma", 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Raymond L. Comenzo, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2003", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00008268"
        }, 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2000", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }, 
    "geocoordinates": {
        "Memorial Sloan-Kettering Cancer Center": "40.714 -74.006"
    }
}